Plus   Neg

Stock Alert: Vertex Pharma Tanks 15% On Stopping Development Of Protein-deficiency Drug

Shares of Vertex Pharmaceuticals Incorporated (VRTX) are falling more than 15% Thursday morning after the company said it has decided to stop the development of its protein-deficiency drug candidate VX-814.

VX-814 was in phase II study in patients with alpha-1 antitrypsin deficiency.

Vertex Pharmaceuticals stock is currently at $229.78. It has been trading in the range of $173.62- $306.08 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health Corp. is hiring 15,000 employees across the U.S. in the fourth quarter to better equip them to tackle the anticipated rise in COVID-19 and flu incidences during the fall and winter months. This is in addition to the recruitment announced in March to fill 50,000 new full-time, part-time and temporary roles across the country in support of the company's response to the pandemic. Ireland's Data Protection Commissioner or DPC, the European Union's main data privacy regulator, is investigating Facebook over its handling of millions of children's personal data on Instagram, reports said. The agency has started two separate inquiries regarding information that email addresses and phone numbers of users under 18 were made public by the Facebook-owned app. ConocoPhillips (COP) and Concho Resources (CXO) announced Monday that they have entered into a definitive agreement to combine companies in an all-stock transaction valued at $9.7 billion. The transaction creates a company with an approximately $60 billion enterprise value and a combined resource...
Follow RTT